Abstract: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in combination with other agents for treatment of disease. Cicletanine, as either a monotherapy or in combination with other drugs, may have the form of a non-racemic mixture of the negative (?) and positive (+) enantiomers of cicletanine, or as either the (?) or (+) enantiomer alone.

Abstract: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications or otherwise treating disease in patients with hypertension, diabetes, metabolic syndrome, obesity and/or other metabolic disorders.

Abstract: The invention provides formulations and methods of use of furopyridine-based compositions alone and in combination with one or more various second therapeutic agents for the treatment of human disease. The furopyridine composition may include one or more furopyridine species, of which cicletanine is an example. The furopyridines may take various enantiomeric forms, ranging from pure (?) through (?)-dominant, racemic and (+)-dominant to pure (+). Second agents may be any drug useful in combination with a furopyridine in the treatment of diseases such as, cardiovascular disease (hypertension, restenosis, etc.), diabetes, diabetes complications, and polycystic ovarian syndrome. Some of these diseases are associated with endothelial dysfunction and imbalances of prostacyclin or of reactive oxygen species (ROS) or reactive nitrogen species (RNS).

Abstract: This invention provides therapeutic compositions of cicletanine and other furopyridines for the treatment of, elevated pulse pressure or isolated systolic hypertension, as well as general hypertension, in monotherapy and in combined therapy with other anti-hypertensive agents (such as organic and inorganic nitrogen donors, calcium channel blockers, diuretics, beta blockers, angiotensin receptor blockers, ACE inhibitors, aldosterone antagonists, renin inhibitors and centrally-acting antihypertensives) cardiovascular agents (such as medications to treat heart failure) and oral antidiabetic agents (such as biguanides and glitazones). Such compositions include enantiomerically pure (positive or negative) embodiments, as well as enantiomeric mixtures other than a racemic mixture, and include daily dosages of less than 50 mg.

Abstract: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in combination with other agents for treatment of disease. Cicletanine, as either a monotherapy or in combination with other drugs, may have the form of a non-racemic mixture of the negative (?) and positive (+) enantiomers of cicletanine, or as either the (?) or (+) enantiomer alone.